Form 4: Verastem Director Gagnon Reports Stock Sales and Option Grant

Director Robert E. Gagnon reports sales of Verastem (VSTM) stock to cover withholding requirements and receives stock options and restricted stock units (RSUs) under the company's equity incentive plan.

Summary

• Robert E. Gagnon, a director of Verastem, Inc. (VSTM), reported the sale of 283 shares of common stock on June 17, 2024, at a price of $3.49 per share to satisfy statutory withholding requirements related to the vesting of restricted stock units (RSUs).
• He also sold 131 shares on June 20, 2024, at $3.21 per share for the same reason.
• On June 18, 2024, Gagnon acquired 8,333 shares of common stock through the grant of RSUs under the company's Amended and Restated 2021 Equity Incentive Plan.
• These RSUs vest in twelve equal monthly installments starting in June 2024 and ending in April 2025, with the final installment vesting no later than May 31, 2025, contingent upon continued service as a director.
• Additionally, Gagnon was granted a stock option to purchase 12,500 shares of common stock at an exercise price of $3.27 on June 18, 2024, which also vests in twelve equal monthly installments over a similar period, expiring on June 18, 2034.
• Following these transactions, Gagnon beneficially owns 35,310 shares of Verastem common stock and 12,500 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are routine and expected, with no significant positive or negative implications for the company's outlook.

Positives

• The grant of RSUs and stock options to a director signals continued alignment of interests between management and shareholders.
• The vesting schedule of the RSUs and stock options incentivizes continued service and contribution from the director.

Negatives

• The sales of shares by the director, even for tax purposes, could be perceived negatively by some investors, although the amounts are relatively small.

Risks

• Continued service as a director is a condition for the vesting of RSUs and stock options; any departure could impact the director's holdings.
• Fluctuations in the stock price could affect the value of the RSUs and stock options.

Future Outlook

The director's future holdings are tied to continued service and the performance of Verastem's stock.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment with company performance.

Comparison to Industry Standards

• Equity grants to directors are a common practice in the biotechnology industry to align their interests with shareholders.
• Vesting schedules are typically structured to incentivize long-term commitment and performance, similar to practices at companies like Amgen and Gilead Sciences.
• The size of the grants and option exercise prices are generally benchmarked against peer companies to ensure competitiveness and attractiveness for board members.

Stakeholder Impact

• Shareholders may view the insider transactions as a routine part of director compensation.
• Employees may see the equity grants as a positive sign of alignment between leadership and company success.

Next Steps

• Continued monitoring of insider transactions to assess alignment with company performance.
• Tracking the vesting of RSUs and stock options to ensure continued service of the director.

Key Dates